Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure  by von Haehling, Stephan et al.
F
S
L
d
B
m
U
C
C
s
Journal of the American College of Cardiology Vol. 50, No. 20, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
PBiomarkers
Comparison of Midregional
Pro-Atrial Natriuretic Peptide With N-Terminal
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Objectives Our aim was assess the prognostic value of midregional pro-atrial natriuretic peptide (MR-proANP) using a new
immunoassay in patients with chronic heart failure (HF).
Background Assessment of natriuretic peptides represents a useful addition in establishing the diagnosis of chronic HF. Their
plasma values are powerful predictors of survival in chronic HF.
Methods We assessed MR-proANP in 525 chronic HF patients (derivation study: age 61  12 years, New York Heart Asso-
ciation (NYHA) functional class I/II/III/IV 6%/44%/41%/9%, N-terminal pro-B-type natriuretic peptide (NT-
proBNP) 3,637  6,362 pg/ml) and validated our findings in 249 additional chronic HF patients (age 63  9
years, NYHA functional class I/II/III/IV 14%/50%/33%/3%, NT-proBNP 1,116  1,991 pg/ml).
Results The MR-proANP levels (mean 339 306 pmol/l, range 24.5 to 2,280 pmol/l) increased with NYHA funcitonal class
(p  0.0001). During follow-up (6 months in survivors), 171 patients (33%) died. Increasing MR-proANP was a pre-
dictor of poor survival (risk ratio 1.35 per increase in standard deviation, 95% confidence interval 1.17 to 1.57; p
0.0061), adjusted for NT-proBNP, age, left ventricular ejection fraction, NYHA functional class, creatinine, and body
mass index (BMI). In receiver operating characteristic curve analysis of 12-month survival, the area under the curve
for MR-proANP was 0.74 and that of NT-proBNP was 0.75 (p 0.7). In a validation study, MR-proANP levels above
the optimal prognostic cutoff value from the validation cohort remained a significant independent predictor of death.
In chronic HF patients in NYHA functional class II to III and all subgroups of BMI and kidney function, MR-proANP
added prognostic value to NT-proBNP. In patients with BMI30 kg/m2, MR-proANP had higher prognostic power
than NT-proBNP.
Conclusions Midregional proANP is an independent predictor of mortality in patients with chronic HF. Midregional proANP
adds prognostic information to NT-proBNP. (J Am Coll Cardiol 2007;50:1973–80) © 2007 by the American
College of Cardiology Foundation
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Measurement of Midregional Pro-ANP in Chronic HF November 13, 2007:1973–80Chronic heart failure (HF) is in-
creasing in prevalence and carries
a devastating prognosis. Early di-
agnosis of chronic HF can im-
prove patient outcome through
timely preventive and therapeutic
measures (1). A wealth of data
suggests that the assessment of
natriuretic peptides represents a
useful addition to the chest X-ray,
electrocardiogram, and Doppler
echocardiography in verifying
the clinical diagnosis of sus-
pected heart failure (2). The
most important members of the
family of natriuretic peptides are
atrial natriuretic peptide (ANP)
and B-type natriuretic peptide
(BNP). Both are markers of car-
iac function and predict survival in patients with chronic
F. In addition to their use in helping to establish the
iagnosis of chronic HF (3,4), they are used in the risk
tratification of patients with stable or recently decompen-
ated chronic HF (5–7) and are considered for guidance in
hronic HF therapy (8).
Both BNP and its precursor N-terminal pro-BNP (NT-
roBNP) are currently used in the assessment of patients
ith chronic HF. Currently, both are considered superior to
NP for diagnostic and prognostic assessment of patients
ith heart failure, mostly because the assessment of ANP is
onsidered less reproducible. However, the concentration of
NP in the circulation is approximately 10 times as high as
hat of BNP (9,10). Atrial natriuretic peptide is derived
rom the cleavage of its precursor pro-atrial natriuretic
eptide (proANP), which is significantly more stable in the
irculation than the mature peptide. Therefore, proANP
as been suggested to be a more reliable analyte (11). The
- and C-terminal regions of propeptides still can undergo
nzymatic degradation (12). Therefore, we developed a new
andwich immunoassay that recognizes a midregional se-
uence of proANP (MR-proANP) (13). We determined
lood levels of MR-proANP in unselected stable patients
ith chronic HF from 4 European centers to find its clinical
orrelates and prognostic usefulness. We compared all
esults to those obtained with NT-proBNP and validated
ur findings in a similar cohort of patients from 1 additional
uropean center.
ethods
e analyzed MR-proANP in a cohort of 525 patients with
hronic HF enrolled at 4 European centers: Athens
Greece; n  59), London (United Kingdom; n  90),
roclaw (Poland; n 247), and Zabrze (Poland; n 129).
total of 249 patients with chronic HF from Verona (Italy)
Abbreviations
and Acronyms
AUC  area under the
receiver-operating
characteristic curve
HF  heart failure
LVEF  left ventricular
ejection fraction
MR-proANP  midregional
pro-atrial natriuretic
peptide
NT-proBNP  N-terminal
pro-B-type natriuretic
peptide
NYHA  New York Heart
Association
ROC  receiver-operating
characteristicerved as the validation sample. All patients participated in
A
Hrojects designed to investigate novel prognostic biochemical
arkers and provided written informed consent. The respec-
ive projects were approved by the local ethics committee at
ach center. The diagnosis of chronic HF was based on
ymptoms and clinical signs according to guidelines issued
y the European Society of Cardiology (14) and the
merican College of Cardiology (15). All patients had a
istory of chronic HF of at least 3 months’ duration and
ocumented left ventricular impairment with a left ventric-
lar ejection fraction (LVEF) 45%. Patients were stable
n medication for at least 4 weeks before the study. The
atients’ clinical characteristics and medication are pre-
ented in Table 1, and biochemical markers are shown in
able 2.
The MR-proANP was analyzed from plasma (78%) or
erum samples immediately frozen at 80°C until analysis.
etection of MR-proANP was performed using a sandwich
mmunoassay (MR-proANP LIA, B.R.A.H.M.S, Hen-
igsdorf/Berlin, Germany) as described in detail elsewhere
13). The functional assay sensitivity (interassay coefficient
f variance 20%) is 20 pmol/l. The stability of MR-
roANP at room temperature is 24 h. After 7 days at
oom temperature, the degradation of MR-proANP does
ot exceed 20%. This assay allows measurement of
R-proANP in serum and plasma (with EDTA, hepa-
in, or citrate) (11). Median MR-proANP in 325 healthy
ndividuals in previous investigations was 45 pmol/l (95%
onfidence interval [CI] 43 to 49 pmol/l) (13). The
T-proBNP levels were determined by a electrochemi-
uminescence immunoassay (ELICIA, Roche Diagnos-
ics, Basel, Switzerland).
ollow-up. The participating centers followed study sub-
ects for a mean of 28 months or until death. The mean
ollow-up in the validation study was 60 months. All
atients’ Clinical Characteristics and Medication
Table 1 Patients’ Clinical Characteristics and Medication
Derivation Study
(n  525)
Validation Study
(n  249) p Value
Age (yrs) 60.8 12.1 63.2 8.9 0.005
Male gender (%) 94 89 0.012
Cause of heart failure
(% ischemic)
73 64 0.014
NYHA functional class
(I/II/III/IV)
6/44/41/9 14/50/33/3 0.0001
Left ventricular ejection
fraction (%)
28.9 8.4 32.2 7.4 0.0001
Patients receiving loop
diuretic (%)
69 89 0.0001
Patients receiving ACE
inhibitor or ARB (%)
88 97 0.0001
Patients receiving beta-
blocker (%)
71 69 0.47
Patients receiving
spironolactone (%)
40 25 0.0001
Patients receiving
aspirin (%)
53 64 0.006CE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; NYHA  New York
eart Association.
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November 13, 2007:1973–80 Measurement of Midregional Pro-ANP in Chronic HFurvivors were followed for at least 8 months. The primary
nd point of the study was cardiovascular mortality.
tatistical analysis. Data are expressed as mean  SD.
he MR-proANP and NT-proBNP data were non-
ormally distributed and, therefore, log-transformed before
nalysis. Student unpaired t test and analysis of variance
ith Fisher post hoc test were used to compare differences
etween groups. Univariate and multivariate regression
nalyses were applied to assess factors that independently
redicted MR-proANP levels. A value of p  0.05 was
onsidered to be significant. To compare different predictive
alues, areas under the receiver-operating characteristic
urve (AUCs) for sensitivity and specificity were con-
tructed. The best prognostic cutoff for survival status was
efined as the highest product of sensitivity and specificity.
o contrast prognostic accuracy, statistical comparison of
eceiver-operating characteristic (ROC) curves was per-
ormed using the method for paired ROC curves described
y Hanley and McNeil (16). The relationship of baseline
ariables with survival was assessed by Cox proportional
azards analysis (single predictor and multivariable analy-
is). Risk ratio (RR) and 95% CI for risk factors and
ignificance level for chi-square (likelihood ratio test) are
iven. To estimate the influence of risk factors on 24-month
urvival, Kaplan-Meier cumulative survival curves were
onstructed for illustrative purposes and compared by the
antel-Haenszel log rank test. All statistics, except analyses
f ROC curves, were performed using StatView 5.0 soft-
are for Windows (Abacus Concepts, Berkeley, California).
he ROC curves were constructed using MedCalc for
indows version 8.2.0.3 (Broekstraat, Mariakerke,
elgium).
esults
erivation study. A total of 525 patients with chronic HF
30 women) were analyzed. The MR-proANP in this study
opulation ranged from 24.5 to 2,280 pmol/l, with a median
f 241 pmol/l (25th percentile 141.75 pmol/l, 75th percentile
Hematologic and Biochemical Parameters
Table 2 Hematologic and Biochemical Param
Derivation Study
(n  525)
n Mean 
Hemoglobin (g/dl) 516 13.9 1
White blood cells (109/l) 365 7.4 2
Sodium (mmol/l) 515 139 5
Potassium (mmol/l) 512 4.4 0
Creatinine (mol/l) 521 111 4
Cholesterol (mmol/l) 507 4.95 1
Triglycerides (mmol/l) 489 1.64 1
MR-proANP (pmol/l) 525 241 [142–
NT-proBNP (pg/ml) 525 1,671 [625–
*Median [25th to 75th percentile].
MR-proANP  midregional pro-atrial natriuretic peptide; NT-proBNP29.75 pmol/l) and a mean of 339  306 pmol/l. Median uR-proANP levels increased with increasing New York
eart Association (NYHA) functional class (Fig. 1). Using
imple regression, we found that MR-proANP correlated
ith NT-proBNP (r  0.80), serum creatinine (r  0.40),
VEF (r  0.27; all p  0.0001), and age (r  0.15; p 
.0006), but not with chronic HF etiology (r  0.001; p 
.98). The chronic HF patients’ medication (Table 1) with
ngiotensin-converting enzyme inhibitors/angiotensin re-
eptor blockers or beta-blockers did not affect MR-proANP
evels (all p  0.4). However, patients on loop diuretics or
pironolactone presented with higher MR-proANP levels
han those not on the drug (loop diuretics: 378  335
mol/l vs. 257  212 pmol/l; spironolactone: 404  355
mol/l vs. 298  263 pmol/l; both p  0.0001). In
ultivariate regression, MR-proANP correlated with
T-proBNP (standardized coefficient [SC]  0.68),
YHA functional class (SC  0.13), and creatinine (SC
0.14; all p  0.0001), weakly with age (SC  0.07; p
0.02), but not with gender, etiology (all p  0.2), or
VEF (SC  0.05; p  0.08).
A total of 171 patients (32.6%) died during follow-up.
aplan-Meier analyses for mortality revealed a 24-month
ortality rate of 29.1% (95% CI 24.8% to 33.4%). Survivors
ad a mean MR-proANP of 271  219 pmol/l, and
onsurvivors 481  398 pmol/l (p  0.0001). The 24-
onth mortality rates according to ascending quartiles of
R-proANP were 5.6% (95% CI 1.5% to 9.7%), 20.7%
95% CI 13.1% to 28.3%), 32.8% (95% CI 23.6% to 42.0%),
nd 54.2% (95% CI 43.9% to 64.5%), respectively (Fig. 2).
everal baseline variables were investigated to determine
heir impact on the end point in single-predictor Cox
egression analysis. Clinically relevant classes were defined
or continuous variables to further characterize their impact
n outcome. Besides MR-proANP (continuous), the fol-
owing were found to have statistically significant effects on
ortality (Table 3): NT-proBNP (continuous), age (con-
inuous), LVEF (continuous and categorized), NYHA
unctional class (categorized), and serum creatinine (contin-
rs
Validation Study
(n  249)
n Mean  SD p Value
235 13.8 1.3 0.73
233 6.8 1.9 0.0008
243 140 3 0.01
242 4.4 0.4 0.2
241 108 30 0.38
199 5.16 0.91 0.04
220 1.96 1.12 0.004
249 148 [99–225]* 0.0001
]* 249 560 [229–1,183]* 0.0001
rminal pro-B-type natriuretic peptide.ete
SD
.6
.2
.5
0
.35
.47
430]*
3,933ous and categorized). Gender (categorized) and chronic
H
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Measurement of Midregional Pro-ANP in Chronic HF November 13, 2007:1973–80F etiology (categorized) had no such effect (Table 3).
djustment for center had no effect (p  0.4).
To define optimal prognostic accuracy of MR-proANP
alues regarding 24-month survival in patients with chronic
F, we performed ROC curve analyses (Fig. 3). For
omparison, the same ROC analyses were performed with
T-proBNP. At 24 months, the AUC for MR-proANP was
.79 and that for NT-proBNP was 0.76 (p 0.12) (Table 4).
he optimal prognostic accuracy for MR-proANP was 295
mol/l. At this cutoff, the sensitivity was 71% and the
pecificity 75% (Table 4). In comparison, the optimal
rognostic cutoff-value for NT-proBNP was 1,770 pg/ml at
hich the sensitivity reached 76% and the specificity 64%.
e calculated ROC curves for different time points during
ollow-up, and it emerged that the AUC values for MR-
Figure 1 MR-proANP and NT-proBNP in the Derivation Cohort
Midregional pro-atrial natriuretic peptide (MR-proANP) (left) and N-terminal pro-B-ty
(right) levels according to New York Heart Association (NYHA) functional class in 5
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Figure 2 Survival During Follow-Up
Kaplan-Meier survival curves subgrouped according to ascending quartiles of MR-proANP and NT-proBNP were similar during the first 12
onths of follow-up but had began to split at 24 months
Table 4). The difference became significant at 48 months,
ith an AUC of 0.79 for MR-proANP and 0.75 for
T-proBNP (p  0.03).
alidation study. These 249 patients with chronic HF
resented with somewhat less severe disease status than
hose in the derivation study (Table 1). The MR-proANP
n the validation sample ranged from 27.9 to 1,310 pmol/l,
ith a median of 148 pmol/l (25th percentile 98.80 pmol/l,
5th percentile 224.75 pmol/l) and a mean of 190  146
mol/l. Levels of MR-proANP correlated with NT-
roBNP (r  0.85), serum creatinine (r  0.45), LVEF (r
0.36), age (r  0.41), and chronic HF etiology (r  0.28;
ll p  0.0001). During follow-up, a total of 68 deaths
riuretic peptide (NT-proBNP)
tients with chronic heart failure in the derivation cohort.
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November 13, 2007:1973–80 Measurement of Midregional Pro-ANP in Chronic HF27.3%) were observed (cardiovascular mortality rate at
4-months: 14.5%, 95% CI 10.2% to 18.8%). Survivors had
mean MR-proANP of 161  108 pmol/l, and nonsurvi-
ors 270  199 pmol/l (p  0.0001). The 24-month
ortality rates according to ascending quartiles of MR-
roANP were 7.9% (95% CI 1.3% to 14.5%), 6.5% (95% CI
.5% to 12.5%), 9.8% (95% CI 2.4% to 17.2%), and 33.8%
95% CI 11.7% to 45.5%), respectively.
We validated our findings from the derivation cohort
sing the optimal cutoff values for both MR-proANP and
T-proBNP derived at 12 months’ follow-up. An MR-
roANP above the optimal cutoff value of 296 pmol/l
emained a significant independent predictor of death in
ingle-Predictor and Multivariable Cox Proportional Hazardodels for Various Clinical Variables (Derivation Study, n  525)
Table 3 Single-Predictor and Multivariable Cox Proportional HaModels for Various Clinical Variables (Derivation Study
Single Predictor M
Variable Chi-Square Risk Ratio
MR-proANP (per SD increase*) 94.1 1.63 (1.4
MR-proANP (below/above median) 49.8 0.30 (0.2
NT-proBNP (per SD increase†) 71.5 1.46 (1.3
NT-proBNP (below/above median) 41.2 0.35 (0.2
Gender (female/male) 2.53 1.65 (0.8
Age (1-yr increase) 6.58 1.02 (1.0
LVEF (20%/20%) 21.3 2.30 (1.6
LVEF (1% increase) 33.1 0.95 (0.9
NYHA functional class (1-class increase) 85.9 2.71 (2.2
Etiology of heart failure (ischemic/nonischemic) 0.09 1.05 (0.7
Creatinine (125/125 mol/l) 30.6 0.42 (0.3
Creatinine (10-mol/l increase) 48.2 1.11 (1.0
Body mass index (1-kg/m2 increase) 14.7 0.93 (0.9
For MR-proANP, 1 SD  306 pmol/l. †For NT-proBNP, 1 SD  6,362 pg/ml.
LVEF  left ventricular ejection fraction; other abbreviations as in Tables 1 and 2.
MR-proANP (pmol/L)
NT-proBNP (pg/mL)
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Figure 3 Sensitivity and Specificity for 24-Month Survival
Receiver operating curves for 24-month survival for MR-proANP
(blue solid line) and NT-proBNP (red dashed line). Abbreviations as in Figure 1.oingle-predictor analysis (RR 2.837, 95% CI 1.702 to 4.728;
hi-square  16.0; p  0.0001) and after adjusting for
T-proBNP, LVEF, NYHA functional class, and creati-
ine (RR 2.10, 95% CI 1.01 to 4.34, chi-square  4.0; p 
.046). Gender, age, etiology, and body mass index (BMI)
ere left out of this model, because they did not predict
urvival in single-predictor analysis in the validation cohort
all p  0.1). The NT-proBNP showed borderline signifi-
ance in single-predictor analysis (RR 2.430, 95% CI 0.976
o 6.054; p  0.057) but failed to do so after adjusting for
he aforementioned covariables (RR 0.99, 95% CI 0.32 to
.07; chi-square 0.1; p  0.98). Other independent
rognosticators in this model were LVEF (p  0.0001) and
YHA functional class (p  0.004).
ubgroup analysis and added prognostic value. After
ombining the derivation and the validation sample (774
atients), we analyzed the prognostic value of MR-proANP
n several important subgroups of patients with chronic HF.
e repeated this analysis for NT-proBNP. We focused on
atients with moderate disease (because their prognosis is
ore difficult to assess than that of patients with very mild
r very severe disease status), on patients in different BMI
ubgroups, and those with different stages of kidney func-
ion (Table 5). The MR-proANP predicted survival in all
ubgroups that we analyzed, having higher prognostic power
han NT-proBNP in patients with obesity. The combina-
ion of the 2 natriuretic peptides showed that the assessment
f MR-proANP on top of NT-proBNP adds prognostic
alue in all subgroups of patients beyond assessing the latter
eptide only (Table 5).
iscussion
his is the first study to evaluate a newly developed
mmunoassay for MR-proANP in the follow-up of a cohort
525)
or Survival Multivariable Model for Survival
CI) p Value Chi-Square Risk Ratio (95% CI) p Value
8) 0.0001 7.5 1.35 (1.17–1.57) 0.0061
2) 0.0001
8) 0.0001 6.4 1.17 (1.04–1.31) 0.0116
8) 0.0001
5) 0.11
3) 0.01 8.4 1.02 (1.01–1.04) 0.0037
8) 0.0001 5.6 1.87 (1.25–2.79) 0.0175
7) 0.0001
5) 0.0001 35.8 2.17 (1.71–2.76) 0.0001
8) 0.77
7) 0.0001 1.1 0.77 (0.53–1.10) 0.29
5) 0.0001
7) 0.0001 0.004 0.99 (0.95–1.03) 0.95zard
, n 
odel f
(95%
8–1.7
2–0.4
4–1.5
5–0.4
9–3.0
0–1.0
1–3.2
3–0.9
0–3.3
5–1.4
1–0.5
8–1.1
0–0.9f patients with chronic HF. In chronic HF, elevated levels
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Measurement of Midregional Pro-ANP in Chronic HF November 13, 2007:1973–80f MR-proANP were associated with an increased risk of
eath, and this effect was independent of other established
rognosticators, including NT-proBNP, LVEF, NYHA
unctional class, creatinine, age, and gender. The AUCs for
R-proANP and NT-proBNP are overlapping to a great
xtent (Table 4), although longer follow-up (4 years) favors
R-proANP. Subgroup analyses revealed that MR-
roANP predicts mortality in several subgroups of patients,
ncluding several important so-called “gray zones” such as
hose with moderate disease, the obese, and those with
ildly impaired kidney function (Table 5). Overall, MR-
roANP adds prognostic information in all subgroups that
e analyzed if assessed in addition to NT-proBNP.
It is increasingly important to establish the added prog-
ostic value of a new parameter over or on top of the
stablished parameter. We documented the added prognos-
ic value of MR-proANP versus NT-proBNP in 2 different
ays. First, we documented the prognostic power of both
arameters in relevant subgroups (Table 5). Second, we
alculated the percentage change in overall prognostic
ower (i.e., the percentage change in chi-squared value) for
ox proportional hazard analysis results for NT-proBNP
lone versus NT-proBNP plus MR-proANP. All subgroups
ox Proportional Hazard Models for MR-proANP and NT-proBNP toubgrou s of P tients With Chronic Heart Failure (Derivation and V
Table 5 Cox Proportional Hazard Models for MR-proANP and NTSubgroups of Patients With Chronic Heart Failure (Der
Disease Severity
NT-proBNP (per SD Increase) (n  774)
Chi-Square RR (95% CI) p Valu
NYHA functional class I to III
(moderate disease)
79.0 1.11 (1.08–1.14) 0.00
BMI 25 kg/m2† 82.7 1.07 (1.05–1.09) 0.00
BMI 25 to 30 kg/m2† 50.4 1.12 (1.08–1.16) 0.00
BMI 30 kg/m2† 4.7 1.03 (0.89–1.19) 0.03
Creatinine 91 mol/l 22.3 2.65 (1.98–3.55) 0.00
Creatinine 91 to 114 mol/l 45.5 1.80 (1.47–2.20) 0.00
Creatinine 114 mol/l 38.6 1.30 (1.19–1.42) 0.00
alculation of the AUCs for MR-proANP and NT-proBNPt Different Time Point During Follow-Up in the Derivation Study
Table 4 Calculation of the AUCs for MR-proANP and NT-proBNPat Different Time Points During Follow-Up in the Deriva
3 Months 6 Months
Patients at risk 488 470
Patients deceased 37 55
MR-proANP
AUC (95% CI) 0.77 (0.73–0.81) 0.75 (0.72–0.
Optimal cut-off (pmol/l) 368 296
Sensitivity (95% CI) 75.7 (58.8–88.2) 80.0 (67.0–89
Specificity (95% CI) 70.3 (66.0–74.3) 63.8 (59.3–68
NT-proBNP
AUC (95% CI) 0.76 (0.72–0.80) 0.74 (0.70–0.
Optimal cut-off (pg/ml) 4,083 4,083
Sensitivity (95% CI) 67.6 (50.2–82.0) 61.8 (47.7–74
Specificity (95% CI) 78.9 (75.0–82.4) 80.0 (76.1–83
p value (between ROC curves) 0.80 0.63
UC  area under the receiver-operating characteristic curve; CI  confidence interval; ROC  reAdded prognostic power if MR-proANP is assessed on top of NT-proBNP. †BMI data were available for 7
BMI  body mass index; RR  risk ratio; other abbreviations as in Tables 1, 2, and 4.hat we analyzed in this way showed added prognostic
ower derived from the additional assessment of MR-
roANP. However, we were able to document a 50%
dded prognostic value for MR-proANP on top of NT-
roBNP in chronic HF patients with a normal kidney
unction and, importantly, in the obese (Table 5).
Both tests used to assess natriuretic peptide levels in this
tudy concern the assessment of propeptides. The N-terminal
egions of both proANP and pro-B-type natriuretic peptide
re subject to structural changes that are dependent on a
umber of external influences. All sandwich immunoassays
eveloped for the detection of proANP use an antibody
gainst the N-terminal region of the peptide. This is
ombined with a secondary antibody against either the
idregion or the C-terminal region (13). However, proteo-
ytic degradation of both proANP and pro-B-type natri-
retic peptide seems to be mainly directed to the N- and the
-terminal parts of the respective precursors. The midre-
ion is significantly more stable (17). In the present study
e therefore used a new sandwich immunoassay, which uses
ntibodies designed to detect the midregion of proANP
Fig. 4). A recent study compared the MR-proANP assay
sed in the present study with NT-proBNP and BNP in the
ct Survival in Differenttion Samples Combi ed)
NP to Predict Survival in Different
n and Validation Samples Combined)
MR-proANP (per SD Increase)
Joint
Chi-Square
Added
Prognostic
Power*Chi-Square RR (95% CI) p Value
89.8 1.19 (1.15–1.23) 0.0001 93.5 18%
74.6 1.14 (1.09–1.19) 0.0001 85.0 3%
61.2 1.31 (1.22–1.40) 0.0001 62.1 23%
11.8 1.59 (1.25–2.01) 0.0006 11.9 100%
35.1 2.69 (2.09–3.45) 0.0001 35.1 57%
51.7 1.94 (1.62–2.34) 0.0001 4.6 20%
35.3 1.41 (1.27–1.56) 0.0001 40.9 6%
Study
12 Months 24 Months 48 Months
406 187 43
89 129 160
0.74 (0.70–0.78) 0.79 (0.74–0.84) 0.79 (0.74–0.84)
296 295 295
74.2 (63.6–80.5) 71.3 (62.7–78.9) 68.0 (59.9–75.4)
66.3 (61.4–70.8) 74.9 (68.0–80.9) 77.8 (70.1–84.3)
0.75 (0.71–0.79) 0.76 (0.71–0.81) 0.75 (0.69–0.80)
4,046 1,770 2,015
58.4 (47.5–68.8) 76.0 (67.7–83.0) 68.0 (59.9–75.4)
82.3 (78.2–85.9) 64.2 (56.8–71.0) 69.4 (61.2–76.8)
0.71 0.12 0.03
perating characteristic; RR  risk ratio; other abbreviations as in Tables 1, 2, and 4.Prediali a
-proB
ivatio
e
01
01
01
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01
01tion
79)
.6)
.2)
78)
.6)
.5)08 of all patients.
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November 13, 2007:1973–80 Measurement of Midregional Pro-ANP in Chronic HFiagnosis of acutely decompensated HF patients presenting to
n emergency department (18). That study demonstrated that
he diagnostic information obtained by MR-proANP mea-
urements was similar to that obtained with either BNP or
T-proBNP measurements (18). This finding indicates
hat some of the previously reported discrepancies on the
iagnostic value between ANP and BNP or their precursors
ould be attributed to differences in assay design and may
ot be present if stable and sensitive assay formats are used.
nother important factor is sample stability, which is 24 h
or MR-proANP at room temperature (13).
The release of ANP is mostly triggered by changes in
trial wall transmural pressure and yields increases in so-
ium and water excretion, suppression of renin and aldo-
terone release, and dilatation of the venous and arterial
ystems (19). An increase in hemodynamic load yields
ncreased secretion of both ANP and BNP (“stretch-
ecretion coupling” [20]). However, the amount of natri-
retic peptides secreted from the atria under those condi-
ions remains higher than that secreted from the ventricular
yocardium (21). Moreover, only secretion of BNP, but not
NP secretion, is significantly increased by tumor necrosis
actor-alpha (22), a proinflammatory cytokine frequently
p-regulated in patients with chronic HF (23). Tumor
ecrosis factor- may therefore contribute to increases in
NP plasma values.
When comparing the performance of 2 well-performing
ests to assess prognosis, it is important to construct ROC
urves, compare sensitivity and specificity, use a derivation
nd validation study approach, and adjust results for relevant
ovariates. Mostly, the prognostic value cannot be compared
y analysis of nominal risk ratios alone. Risk ratios refer to
he change in risk relative to a given change in the parameter
f interest. The concentration of natriuretic peptides in the
99891 126
PEVPPWTGEVSPAQRDGGAL GRGPWDSSDRSALLKSKL
Polystyrene Tube
ANPSignalling
Peptide
N-terminal proANP
proANP
MR-proANP
Figure 4 Detection of MR-proANP
Sequence of pro-atrial natriuretic peptide (proANP) used for the detection of
MR-proANP and principle of the test, making use of a primary antibody that is
coated on a polystyrene tube and a secondary signaling antibody. Abbrevia-
tions as in Figure 1.lood of chronic HF patients can vary over a wide range ofevels, and therefore results are typically expressed per unit
hange in peptide. This reference unit change can be freely
hosen depending on the overall range of plasma levels and
ersonal preference, and therefore RRs can be very different
ithout any change in the true prognostic power of the
iven variable. We therefore used the standard deviation to
ompare the 2 markers analyzed in the present study.
nother important issue is that when strong prognosticators
re compared, the p value is of little help in comparing these
rognosticators unless it is calculated to far more than 4
ecimals. The comparative overall prognostic power can
herefore best be seen in the chi-squared value as derived
rom Cox proportional hazard analysis.
tudy limitations. First, the present study populations
onsisted mainly of male patients, and it is unknown
hether the findings can be extrapolated to female patients.
oreover, the number of patients in NYHA functional
lass I was small (9% of all patients). This has to be kept in
ind when the data are being interpreted.
onclusions
e have documented the independent prognostic power of
R-proANP as assessed with a newly developed immuno-
ssay in two cohorts of patients with chronic HF. The
R-proANP levels strongly correlate with disease severity.
he power of MR-proANP to predict prognosis is at least as
arge as that of NT-proBNP, and MR-proANP adds prog-
ostic information to NT-proBNP across all disease stages and
ubgroups of chronic HF analyzed in this study.
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